Ocugen Inc (OCGN)
$0.92
0.04 (4.91%)
OCGN Stock Quote Delayed 30 Minutes
7 Heavily Shorted Penny Stocks for Your Short-Squeeze Watch List
Here are seven heavily shorted penny stocks that can potentially witness a sharp reversal rally in the foreseeable future.
11 Best Stocks to Buy for 2023
INSIDE: Investing legend Louis Navellier reveals his Top 11 Stocks for 2023 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
183.49M
PE Ratio
-2.43
EPS
-0.38
Volume (Avg. Vol.)
4.15M
Day's Range
$0.87 - $0.94
52-Week Range
$0.85 - $3.76
Dividend & Yield
N/A (N/A)
OCGN Stock Predictions, Articles, and Ocugen Inc News
OCGN Stock Alert: What to Know About Ocugen’s Latest Phase 3 Clinical Trial
OCGN stock fell into the red despite Ocugen's success in advancing a regenerative cell therapy product evaluation.
Why Is Ocugen (OCGN) Stock Up Today?
OCGN stock is getting a boost today on news that Ocugen is partnering with Washington University on its Covid-19 vaccine.
Why Is Ocugen (OCGN) Stock Climbing Higher Today?
Ocugen (OCGN) stock is gaining on Tuesday after Mizuho Securities analysts initiated coverage of the medical company's shares.
7 Stocks to Short Before July 2022
There are many highly overvalued publicly traded companies that will have trouble staying afloat, giving investors many stocks to short.
OCGN Stock Falls Despite Positive FDA Update
Shares of the biotech company are falling despite news that the FDA has cleared it to resume clinical trials of its Covid-19 vaccine.
The Top Reasons to Avoid the Ocugen Stock
WIth Ocugen, there’s nothing to get excited about here. Avoid the OCGN stock, as it heads significantly lower.
State Street Just Bought Ocugen (OCGN) Stock. Here’s Why.
OCGN stock has declined by over 90% in the past five years. However, that hasn't stopped State Street from more than doubling its position.
Why Is Ocugen (OCGN) Stock Down Today?
Shares of OCGN stock are trading lower after the FDA announced that it had placed a clinical hold on Covaxin. Here's what you should know.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
If you're looking for the biggest pre-market stock movers for Monday, we've got you covered with a list of gainers and losers for today.
It’s Time to Get Clinical, Not Cynical, With Ocugen Stock
The selling pressure on OCGN stock has been as heavy as a rock, but worried shareholders should celebrate Ocugen's breakthrough moments.
Why Is Ocugen (OCGN) Stock Up 10% Today?
Sometimes, improved investor sentiment and a revamped website is enough of a catalyst to take something like OCGN stock on a 10% ride higher.
The Biggest Reasons to Avoid Ocugen for Now
Ocugen was once one of the hottest stocks on the market. After soaring from 18 cents to $17.6 back to about $2.5. I simply wouldn’t touch it.
Why Is Ocugen (OCGN) Stock Up Today?
Biotechnology company Ocugen is grabbing headlines today after jumping more than 15%. Is OCGN stock making a comeback?
Ocugen Is Two Strikes in With a Third in the Books
Ocugen has tried repeatedly to bring drugs to market, first as Histogenics and later under its current name.
Why Is Ocugen (OCGN) Stock Down Today?
Shares of OCGN stock are in the red after the company's Covaxin Covid-19 vaccine was declined EUA by the FDA. Here's what you should know.
Ocugen Latest News: What OCGN Stock Investors Need to Know About the FDA’s Covaxin Rejection
Ocugen (OCGN) stock is falling hard on Friday after the FDA rejected its Emergency Use Authorization request for Covaxin.
Is OCGN Stock a Buy After 20% Plunge? One Analyst Thinks It Can Go to $15.
Ocugen is down more than 20% after announcing a common stock offering. Could this possibly present a buying opportunity for OCGN stock?
